Results 81 to 90 of about 9,430 (168)

Golimumab for the treatment of ulcerative colitis

Clinical and Experimental Gastroenterology, 2014
Mark Löwenberg,1 Nanne KH de Boer,2 Frank Hoentjen3 1Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands; 2Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, the ...
Löwenberg M, de Boer NKH, Hoentjen F   +2 more
doaj  

The Longer‐Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population‐Based Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background and Aims In 2019, British Columbia (BC) became the first jurisdiction in North America to introduce a mandatory non‐medical switching (NMS) policy requiring patients with Crohn's disease (CD) and ulcerative colitis (UC) to be switched from originator biologics to biosimilar equivalents.
Mark Harrison, Sandra Blitz, Michael Law, Mina Tadrous, Tara Gomes, Fiona Clement, Greg Rosenfeld, Aslam Anis, Nick Bansback   +8 more
wiley   +1 more source

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL‐23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real‐life data are scant. We aimed to evaluate the effectiveness and safety of MIRI in a real‐world setting.
Giuseppe Costantino, Anna Viola, Andrea Iuculano, Fabio Salvatore Macaluso, Raffaele Li Voti, Maria Cappello, Chiara Antoci, Concetta Ferracane, Morena Sciuto, Domenico Catarella, Stefanie Parisi, Filippo Mocciaro, Barbara Scrivo, Maria Emanuela Distefano, Roberto Vassallo, Maria Giovanna Minissale, Giuseppe Scalisi, Serena Garufi, Sofia Rao, Stefano Muscarella, Vincenza Tortorella, Emiliano Giangreco, Marco Muscianisi, Ambrogio Orlando, Walter Fries   +24 more
wiley   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Exposure to golimumab during pregnancy: Results from the Company's global safety database

Pharmacology Research & Perspectives
Data on the use of golimumab (GLM) during pregnancy are limited. This study evaluated pregnancy outcomes in women treated with GLM during pregnancy. Cumulative data on GLM‐exposed pregnancies from the Company's global safety database (GSD) are summarized.
Marijo Otero‐Lobato, Adesoji Adeyemo, Michelle Higley, Kathleen G. Lomax, Anja Geldhof, Suzan Esslinger   +5 more
doaj   +1 more source

A Rare Hypersensitivity Reaction with Golimumab: Recurrent Fever After Each Injection

Türk Osteoporoz Dergisi
Ankylosing spondylitis (AS) is a chronic inflammatory disease treated with non-steroidal anti-inflammatory drugs (NSAIDs) and, in refractory cases, biologic agents such as tumor necrosis factor inhibitors (TNF-Is).
Berna Günay, Nilgün Mesci, Duygu Geler Külcü, Merve Özdemir   +3 more
doaj   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1206-1209, June 2026.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Incorporating alternative design clinical trials in network meta-analyses

Clinical Epidemiology, 2014
Kristian Thorlund,1–3 Eric Druyts,1,4 Kabirraaj Toor,1,5 Jeroen P Jansen,1,6 Edward J Mills1,3 1Redwood Outcomes, Vancouver, BC, 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; 3Stanford Prevention
Thorlund K, Druyts E, Toor K, Jansen JP, Mills EJ   +4 more
doaj  

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

Patient Preference and Adherence, 2018
Séverine Vermeire,1 François D’heygere,2 Antoine Nakad,3 Denis Franchimont,4 Fernand Fontaine,5 Edouard Louis,6 Philippe Van Hootegem,7 Olivier Dewit,8 Guy Lambrecht,9 Beatrijs Strubbe,10 Filip Baert11 1Department of Gastroenterology,
Vermeire S, D'heyghere F, Nakad A, Franchimont D, Fontaine F, Louis E, Van Hootegem P, Dewit O, Lambrecht G, Strubbe B, Baert F   +10 more
doaj  

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study. [PDF]

Inflamm Bowel Dis
Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS.   +13 more
europepmc   +1 more source